Literature DB >> 8547499

Herpesvirus infections in persons infected with human immunodeficiency virus.

J A Stewart1, S E Reef, P E Pellett, L Corey, R J Whitley.   

Abstract

Herpesviruses are among the most common causes of infections of humans. Viruses in this family share the unique biological property of being able to establish latency and to recur. Furthermore, chronic excretion of virus is not uncommon. In the immunocompromised host, including persons with human immunodeficiency virus (HIV) infection, herpesvirus disease can be particularly severe, resulting in chronic, persistent, active infection and, in some cases, life-threatening disease. The most pathogenic of the herpesviruses in patients with AIDS include herpes simplex viruses, human cytomegalovirus, and varicella-zoster virus. Disease caused by Epstein-Barr virus, particularly opportunistic malignancies, has been recognized. A new herpesvirus that is associated with Kaposi's sarcoma was recently described. On the other hand, disease caused by human herpesviruses 6 and 7 in persons infected with HIV remains to be unequivocally recognized. Prevention of exposure to herpesviruses, disease, and recurrence requires different measures than those for some of the other opportunistic infections in HIV-infected patients; this is because herpesvirus disease develops in most of these individuals as a result of reactivation rather than primary infection. Thus, approaches to the prevention and control of herpesvirus infections must be individualized according to both the type of virus as well as the type of infection (i.e., primary or recurrent). We discuss recommended measures for the prevention and control of these infections.

Entities:  

Mesh:

Year:  1995        PMID: 8547499     DOI: 10.1093/clinids/21.supplement_1.s114

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir.

Authors:  Stephen L Sacks; Fred Y Aoki
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Taking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existing and upcoming challenges.

Authors:  S Augustine; R A Bonomo
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-09-09

Review 3.  Pediatric human immunodeficiency virus infection.

Authors:  J B Domachowske
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.

Authors:  Bruno Sainz; William P Halford
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96.

Authors:  J A Schwartz; E K Lium; S J Silverstein
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 6.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

Review 7.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Genital herpes: review of the epidemic and potential use of type-specific serology.

Authors:  R L Ashley; A Wald
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation.

Authors:  Thomas L Cherpes; James L Busch; Brian S Sheridan; Stephen A K Harvey; Robert L Hendricks
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells.

Authors:  Jeremy R Teuton; Curtis R Brandt
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.